Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy of Dendritic and Cytokine-induced Killer Cells (DC-CIK) for hepatocellular carcinoma (HCC).
About 60 patients with HCC, who had received complete resection or TACE and got Complete remission (CR) or partial response (PR), will be randomly divided into group A (receive DC-CIK treatment) or group B (just regularly follow up), and the randomize ratio will be 1:1. Patients in group A will receive 2-3 cycles of DC-CIK cells treatment (every 4 weeks). Patients in group B will have no anti-tumor therapy. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03007212 -
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
|
Phase 4 | |
| Terminated |
NCT03236649 -
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
|
Phase 3 | |
| Withdrawn |
NCT04044326 -
The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors
|
N/A | |
| Recruiting |
NCT04687969 -
Multimodal Machine Learning Characterization of Solid Tumors
|
||
| Completed |
NCT02562755 -
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
|
Phase 3 | |
| Withdrawn |
NCT02406508 -
Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC
|
Phase 2 | |
| Completed |
NCT01972672 -
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT01247298 -
A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
|
Phase 0 | |
| Completed |
NCT03735628 -
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT02188901 -
Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study
|
N/A | |
| Active, not recruiting |
NCT04522908 -
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
|
Phase 2 | |
| Terminated |
NCT01433016 -
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
|
Phase 2 | |
| Withdrawn |
NCT04465734 -
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
|
Phase 3 | |
| Recruiting |
NCT05057013 -
HMBD-001 in Advanced HER3 Positive Solid Tumours
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03753659 -
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
| Completed |
NCT03516071 -
A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC
|
Phase 2 | |
| Completed |
NCT01761266 -
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
|
Phase 3 | |
| Completed |
NCT02794805 -
Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis
|
Phase 2 | |
| Completed |
NCT02541149 -
Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma
|
N/A |